{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T20:06:00Z","timestamp":1769112360098,"version":"3.49.0"},"reference-count":31,"publisher":"e-Century Publishing Corporation","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Transl Res"],"DOI":"10.62347\/gtwq2803","type":"journal-article","created":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T07:08:06Z","timestamp":1759043286000},"page":"7283-7291","source":"Crossref","is-referenced-by-count":0,"title":["Enhanced efficacy and safety of combining Aidi injection with megestrol acetate for endometrial cancer treatment"],"prefix":"10.62347","volume":"17","author":[{"given":"Qinglin","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.rcl.2023.02.007","article-title":"Imaging of endometrial cancer","volume":"61","author":"Sbarra","year":"2023","unstructured":"Sbarra M, Lupinelli M, Brook OR, Venkatesan AM and Nougaret S. Imaging of endometrial cancer. Radiol Clin North Am 2023; 61: 609-625.","journal-title":"Radiol Clin North Am"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1007\/s00404-024-07463-9","article-title":"Current practice with operative hysteroscopy for fertility preservation in endometrial cancer and endometrial premalignancies","volume":"309","author":"Bilir","year":"2024","unstructured":"Bilir E, Kacperczyk-Bartnik J, Bizzarri N and Kahramanoğlu İ. Current practice with operative hysteroscopy for fertility preservation in endometrial cancer and endometrial premalignancies. Arch Gynecol Obstet 2024; 309: 2267-2278.","journal-title":"Arch Gynecol Obstet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1349804","DOI":"10.3389\/fendo.2024.1349804","article-title":"Editorial: the roles of micro-RNAs in neuroendocrine systems","volume":"15","author":"Mounien","year":"2024","unstructured":"Mounien L, Nakamura K, Chigr F and Maekawa F. Editorial: the roles of micro-RNAs in neuroendocrine systems. Front Endocrinol (Lausanne) 2024; 15: 1349804.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"11795549231215966","DOI":"10.1177\/11795549231215966","article-title":"Exosomes in cancer: diagnostic and therapeutic applications","volume":"18","author":"Maqsood","year":"2024","unstructured":"Maqsood Q, Sumrin A, Saleem Y, Wajid A and Mahnoor M. Exosomes in cancer: diagnostic and therapeutic applications. Clin Med Insights Oncol 2024; 18: 11795549231215966.","journal-title":"Clin Med Insights Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/ijgc-2022-003675","article-title":"Immunotherapy in endometrial cancer","volume":"33","author":"Mahdi","year":"2023","unstructured":"Mahdi H, Chelariu-Raicu A and Slomovitz BM. Immunotherapy in endometrial cancer. Int J Gynecol Cancer 2023; 33: 351-357.","journal-title":"Int J Gynecol Cancer"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/s00066-020-01735-4","article-title":"The PORTEC-3 trial for high-risk endometrial cancer: impact of molecular classification on prognosis and benefit from adjuvant therapy","volume":"197","author":"Marnitz","year":"2021","unstructured":"Marnitz S and Schömig-Markiefka B. The PORTEC-3 trial for high-risk endometrial cancer: impact of molecular classification on prognosis and benefit from adjuvant therapy. Strahlenther Onkol 2021; 197: 266-268.","journal-title":"Strahlenther Onkol"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Malentacchi F, Turrini I, Sorbi F, Projetto E, Castiglione F, Vergoni F, Amunni G, Fambrini M, Petraglia F, Noci I and Pillozzi S. Identification of a gene panel for endometrioid endometrial cancer: a possible prognostic value? Reprod Sci 2020; 27: 592-598.","DOI":"10.1007\/s43032-019-00059-8"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3390\/jpm11010048","article-title":"Risk reclassification of patients with endometrial cancer based on tumor molecular profiling: first real world data","volume":"11","author":"Oberndorfer","year":"2021","unstructured":"Oberndorfer F, Moling S, Hagelkruys LA, Grimm C, Polterauer S, Sturdza A, Aust S, Reinthaller A, Müllauer L and Schwameis R. Risk reclassification of patients with endometrial cancer based on tumor molecular profiling: first real world data. J Pers Med 2021; 11: 48.","journal-title":"J Pers Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1244634","DOI":"10.3389\/fmed.2023.1244634","article-title":"Recent management of endometrial cancer: a narrative review of the literature","volume":"10","author":"Pados","year":"2023","unstructured":"Pados G, Zouzoulas D and Tsolakidis D. Recent management of endometrial cancer: a narrative review of the literature. Front Med (Lausanne) 2023; 10: 1244634.","journal-title":"Front Med (Lausanne)"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.4274\/jtgga.galenos.2021.2020.0120","article-title":"Identification and characterization of endometrial carcinoma with tumor markers HE4 and CA125 in serum and endometrial tissue samples","volume":"22","author":"Cuesta-Guardiola T","year":"2021","unstructured":"Cuesta-Guardiola T, Carretero AQ, Martinez-Martinez J, Cuñarro-López Y, Pereira-Sánchez A, Fernández-Corona A and de Leon-Luis JA. Identification and characterization of endometrial carcinoma with tumor markers HE4 and CA125 in serum and endometrial tissue samples. J Turk Ger Gynecol Assoc 2021; 22: 161-167.","journal-title":"J Turk Ger Gynecol Assoc"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"9367","DOI":"10.1007\/s13277-016-4784-9","article-title":"Monitoring the treatment outcome in endometrial cancer patients by CEA and TATI","volume":"37","author":"Kozakiewicz","year":"2016","unstructured":"Kozakiewicz B, Chądzyńska M, Dmoch-Gajzlerska E and Stefaniak M. Monitoring the treatment outcome in endometrial cancer patients by CEA and TATI. Tumour Biol 2016; 37: 9367-9374.","journal-title":"Tumour Biol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.ejso.2019.11.519","article-title":"Comparison of minimally invasive surgery with laparotomic approach in the treatment of high risk endometrial cancer: a systematic review","volume":"46","author":"Scaletta","year":"2020","unstructured":"Scaletta G, Dinoi G, Capozzi V, Cianci S, Pelligra S, Ergasti R, Fagotti A, Scambia G and Fanfani F. Comparison of minimally invasive surgery with laparotomic approach in the treatment of high risk endometrial cancer: a systematic review. Eur J Surg Oncol 2020; 46: 782-788.","journal-title":"Eur J Surg Oncol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"106832","DOI":"10.1016\/j.yebeh.2019.106832","article-title":"Exploiting cannabinoid and vanilloid mechanisms for epilepsy treatment","volume":"121","author":"Asth","year":"2021","unstructured":"Asth L, Iglesias LP, De Oliveira AC, Moraes MFD and Moreira FA. Exploiting cannabinoid and vanilloid mechanisms for epilepsy treatment. Epilepsy Behav 2021; 121: 106832.","journal-title":"Epilepsy Behav"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"81","DOI":"10.23736\/S0026-4806.20.07081-0","article-title":"Quality of life and sexual functioning of patient affected by endometrial cancer","volume":"112","author":"Cianci","year":"2021","unstructured":"Cianci S, Rosati A, Capozzi VA, Tarascio M, Uccella S, Palumbo M and Caruso S. Quality of life and sexual functioning of patient affected by endometrial cancer. Minerva Med 2021; 112: 81-95.","journal-title":"Minerva Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s12032-023-01956-4","article-title":"Clinical application of liquid biopsy in endometrial carcinoma","volume":"40","author":"Shen","year":"2023","unstructured":"Shen Y, Shi R, Zhao R and Wang H. Clinical application of liquid biopsy in endometrial carcinoma. Med Oncol 2023; 40: 92.","journal-title":"Med Oncol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ygyno.2017.11.019","article-title":"The unrecognized burden of cardiovascular risk factors in women newly diagnosed with endometrial cancer: a prospective case control study","volume":"148","author":"Kitson","year":"2018","unstructured":"Kitson SJ, Lindsay J, Sivalingam VN, Lunt M, Ryan NAJ, Edmondson RJ, Rutter MK and Crosbie EJ. The unrecognized burden of cardiovascular risk factors in women newly diagnosed with endometrial cancer: a prospective case control study. Gynecol Oncol 2018; 148: 154-160.","journal-title":"Gynecol Oncol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"5652","DOI":"10.18632\/oncotarget.23790","article-title":"Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer","volume":"9","author":"Yamashita","year":"2017","unstructured":"Yamashita H, Nakayama K, Ishikawa M, Nakamura K, Ishibashi T, Sanuki K, Ono R, Sasamori H, Minamoto T, Iida K, Sultana R, Ishikawa N and Kyo S. Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer. Oncotarget 2017; 9: 5652-5664.","journal-title":"Oncotarget"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ygyno.2018.05.028","article-title":"Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor","volume":"150","author":"Gockley","year":"2018","unstructured":"Gockley AA, Kolin DL, Awtrey CS, Lindeman NI, Matulonis UA and Konstantinopoulos PA. Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor. Gynecol Oncol 2018; 150: 219-226.","journal-title":"Gynecol Oncol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/path.5004","article-title":"Blocking 17β-hydroxysteroid dehydrogenase type 1 in endometrial cancer: a potential novel endocrine therapeutic approach","volume":"244","author":"Konings","year":"2018","unstructured":"Konings GF, Cornel KM, Xanthoulea S, Delvoux B, Skowron MA, Kooreman L, Koskimies P, Krakstad C, Salvesen HB, van Kuijk K, Schrooders YJ, Vooijs M, Groot AJ, Bongers MY, Kruitwagen RF and Romano A. Blocking 17β-hydroxysteroid dehydrogenase type 1 in endometrial cancer: a potential novel endocrine therapeutic approach. J Pathol 2018; 244: 203-214.","journal-title":"J Pathol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3390\/medicina60050733","article-title":"The impact of positive peritoneal cytology on the survival rates of early-stage-disease endometrial cancer patients: systematic review and meta-analysis","volume":"60","author":"Pergialiotis","year":"2024","unstructured":"Pergialiotis V, Panagiotopoulos M, Koutras A, Daras A, Ntounis T, Liontos M, Daskalakis G and Thomakos N. The impact of positive peritoneal cytology on the survival rates of early-stage-disease endometrial cancer patients: systematic review and meta-analysis. Medicina (Kaunas) 2024; 60: 733.","journal-title":"Medicina (Kaunas)"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1038\/s41379-018-0039-1","article-title":"Indoleamine 2,3-dioxygenase in endometrial cancer: a targetable mechanism of immune resistance in mismatch repair-deficient and intact endometrial carcinomas","volume":"31","author":"Mills","year":"2018","unstructured":"Mills A, Zadeh S, Sloan E, Chinn Z, Modesitt SC and Ring KL. Indoleamine 2,3-dioxygenase in endometrial cancer: a targetable mechanism of immune resistance in mismatch repair-deficient and intact endometrial carcinomas. Mod Pathol 2018; 31: 1282-1290.","journal-title":"Mod Pathol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/CEJ.0000000000000449","article-title":"Association of BMI and height with the risk of endometrial cancer, overall and by histological subtype: a population-based prospective cohort study in Japan","volume":"28","author":"Kawachi","year":"2019","unstructured":"Kawachi A, Shimazu T, Budhathoki S, Sawada N, Yamaji T, Iwasaki M, Inoue M and Tsugane S; JPHC Study Group. Association of BMI and height with the risk of endometrial cancer, overall and by histological subtype: a population-based prospective cohort study in Japan. Eur J Cancer Prev 2019; 28: 196-202.","journal-title":"Eur J Cancer Prev"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s11626-024-00885-4","article-title":"Role of the Ror family receptors in Wnt5a signaling","volume":"60","author":"Kamizaki","year":"2024","unstructured":"Kamizaki K, Minami Y and Nishita M. Role of the Ror family receptors in Wnt5a signaling. In Vitro Cell Dev Biol Anim 2024; 60: 489-501.","journal-title":"In Vitro Cell Dev Biol Anim"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"953115","DOI":"10.3389\/fimmu.2022.953115","article-title":"Targeting immunometabolism mediated by the IDO1 pathway: a new mechanism of immune resistance in endometrial cancer","volume":"13","author":"Passarelli","year":"2022","unstructured":"Passarelli A, Pisano C, Cecere SC, Di Napoli M, Rossetti S, Tambaro R, Ventriglia J, Gherardi F, Iannacone E, Venanzio SS, Fiore F, Bartoletti M, Scognamiglio G, Califano D and Pignata S. Targeting immunometabolism mediated by the IDO1 pathway: a new mechanism of immune resistance in endometrial cancer. Front Immunol 2022; 13: 953115.","journal-title":"Front Immunol"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Altındağ SD, Yiğit S and Şen S. Is microcystic, elongated, and fragmented pattern of myometrial invasion in endometrioid endometrial carcinoma associated with survival? Turk J Med Sci 2022; 52: 1569-1579.","DOI":"10.55730\/1300-0144.5497"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1186\/s12905-022-02079-0","article-title":"Predictive models for overall survival in breast cancer patients with a second primary malignancy: a real-world study in Shanghai, China","volume":"22","author":"Yuan","year":"2022","unstructured":"Yuan L, Chen Y, Li X, Jin H and Shi J. Predictive models for overall survival in breast cancer patients with a second primary malignancy: a real-world study in Shanghai, China. BMC Womens Health 2022; 22: 498.","journal-title":"BMC Womens Health"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s00428-020-03007-z","article-title":"ESGO\/ESTRO\/ESP Guidelines for the management of patients with endometrial carcinoma","volume":"478","author":"Concin","year":"2021","unstructured":"Concin N, Creutzberg CL, Vergote I, Cibula D, Mirza MR, Marnitz S, Ledermann JA, Bosse T, Chargari C, Fagotti A, Fotopoulou C, González-Martín A, Lax SF, Lorusso D, Marth C, Morice P, Nout RA, O’Donnell DE, Querleu D, Raspollini MR, Sehouli J, Sturdza AE, Taylor A, Westermann AM, Wimberger P, Colombo N, Planchamp F and Matias-Guiu X. ESGO\/ESTRO\/ESP Guidelines for the management of patients with endometrial carcinoma. Virchows Arch 2021; 478: 153-190.","journal-title":"Virchows Arch"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"6053406","DOI":"10.1155\/2021\/6053406","article-title":"Effect of combination of Traditional Chinese Medicine with Western Medicine on Endometrial Carcinoma and its influence on ultrasound, MRI, tumor markers HE4 and CA125","volume":"2021","author":"Gao","year":"2021","unstructured":"Gao X, Li Q, Qu Y, Zhang J, Xing Y and Li S. Effect of combination of Traditional Chinese Medicine with Western Medicine on Endometrial Carcinoma and its influence on ultrasound, MRI, tumor markers HE4 and CA125. Evid Based Complement Alternat Med 2021; 2021: 6053406.","journal-title":"Evid Based Complement Alternat Med"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3233\/CBM-190099","article-title":"Overexpression of connective tissue growth factor is associated with tumor progression and unfavorable prognosis in endometrial cancer","volume":"25","author":"XT","year":"2019","unstructured":"Li XT, Li JY, Zeng GC, Lu L, Jarrett MJ, Zhao Y, Yao QZ, Chen X and Yu KJ. Overexpression of connective tissue growth factor is associated with tumor progression and unfavorable prognosis in endometrial cancer. Cancer Biomark 2019; 25: 295-302.","journal-title":"Cancer Biomark"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"4815","DOI":"10.3390\/cancers15194815","article-title":"Preoperative serum levels of PDGF-AB, PDGF-BB, TGF-α, EGF and ANG-2 in the diagnosis of endometrial cancer","volume":"15","author":"Koz&#x142","year":"2023","unstructured":"Kozłowski M, Borzyszkowska D, Mirko J, Turoń-Skrzypińska A, Piotrowska K, Tołoczko-Grabarek A, Kwiatkowski S, Tarnowski M, Rotter I and Cymbaluk-Płoska A. Preoperative serum levels of PDGF-AB, PDGF-BB, TGF-α, EGF and ANG-2 in the diagnosis of endometrial cancer. Cancers (Basel) 2023; 15: 4815.","journal-title":"Cancers (Basel)"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1112987","DOI":"10.3389\/fendo.2022.1112987","article-title":"Prolactin receptor signaling: a novel target for cancer treatment - Exploring anti-PRLR signaling strategies","volume":"13","author":"Standing","year":"2022","unstructured":"Standing D, Dandawate P and Anant S. Prolactin receptor signaling: a novel target for cancer treatment - Exploring anti-PRLR signaling strategies. Front Endocrinol (Lausanne) 2022; 13: 1112987.","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["American Journal of Translational Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/9\/ajtr0165555.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T03:56:11Z","timestamp":1769054171000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/9\/ajtr0165555.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":31,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/gtwq2803","relation":{},"ISSN":["1943-8141"],"issn-type":[{"value":"1943-8141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}